SS-31 Beginners Guide — Real Peptides

Most cellular dysfunction begins at the same place: inside the mitochondria, where energy production breaks down long before symptoms appear. SS-31 (elamipretide) is one of very few research compounds that can cross the mitochondrial membrane, bind directly to cardiolipin. The phospholipid that anchors respiratory chain proteins. And restore electron transport function without relying on surface receptor signaling. That's not how most therapeutic peptides work.

We've synthesized hundreds of peptide batches across multiple compound classes. The difference between membrane-permeable mitochondrial-targeting peptides like SS-31 Elamipretide and receptor-dependent compounds isn't just pharmacological. It's structural, requiring exact amino-acid sequencing to preserve cell-penetrating capacity.

What is SS-31 and how does it work at the cellular level?

SS-31 (D-Arg-2′,6′-Dmt-Lys-Phe-NH₂) is a tetrapeptide containing dimethyltyrosine residues that allow it to selectively accumulate at the inner mitochondrial membrane, where it binds cardiolipin. The phospholipid responsible for organizing respiratory chain supercomplexes. By stabilizing cardiolipin, SS-31 prevents cytochrome c dissociation, reduces reactive oxygen species (ROS) generation at complex I and III, and preserves ATP synthesis efficiency under oxidative stress conditions. Unlike CoQ10 or other mitochondrial antioxidants, SS-31 doesn't scavenge ROS. It prevents their formation by optimizing electron flow.

Yes, SS-31 improves mitochondrial function. But not through antioxidant scavenging, membrane fluidity changes, or receptor activation. It works by physically stabilizing the cardiolipin-cytochrome c interaction, which becomes disrupted in aging, ischemia-reperfusion injury, heart failure, and neurodegenerative states. This SS-31 beginners guide covers the exact mechanism, dosing protocols used in clinical trials, reconstitution and storage requirements, and how to evaluate peptide purity when selecting a research supplier.

Why SS-31 Targets Mitochondrial Cardiolipin and Not Cellular Receptors

SS-31's pharmacological activity begins at the mitochondrial inner membrane. Not at G protein-coupled receptors, growth factor receptors, or nuclear hormone receptors. This distinction matters because most therapeutic peptides (BPC-157, Thymosin Alpha-1, GLP-1 agonists) require receptor binding to initiate downstream signaling cascades. SS-31 bypasses that entirely.

Cardiolipin is a unique phospholipid found almost exclusively in mitochondria, where it comprises 15–20% of inner membrane lipid content. Its four acyl chains anchor electron transport chain complexes I, III, IV, and V into supercomplexes. Physical assemblies that optimize electron transfer efficiency and minimize ROS leakage. When cardiolipin is oxidized (by hydroxyl radicals, peroxynitrite, or lipid peroxidation), cytochrome c dissociates from the membrane and initiates apoptotic signaling. SS-31 prevents that dissociation.

The peptide contains alternating cationic (arginine, lysine) and aromatic (dimethyltyrosine, phenylalanine) residues. This arrangement creates both positive charge. Which attracts SS-31 to the negatively charged inner membrane. And hydrophobic interactions that insert the peptide into the lipid bilayer adjacent to cardiolipin. Once there, SS-31 forms hydrogen bonds with cardiolipin headgroups, stabilizing the phospholipid conformation and preventing oxidative damage to the acyl chains.

In a 2014 randomized controlled trial published in the Journal of the American College of Cardiology, SS-31 reduced myocardial infarct size by 21% when administered during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction. An effect attributed to preserved mitochondrial membrane potential and reduced cytochrome c release. The mechanism was cardiolipin stabilization during ischemia-reperfusion, not anti-inflammatory signaling or receptor-mediated cardioprotection.

Here's the practical distinction for researchers: receptor-targeted peptides require cell-type-specific expression of the cognate receptor to exert effects. SS-31 works in any cell type with high mitochondrial density. Cardiomyocytes, neurons, skeletal muscle, renal tubular cells, hepatocytes. The mitochondria are the target, not the cell surface.

Dosing, Reconstitution, and Administration Protocols From Clinical Trials

SS-31 has been evaluated in multiple Phase I and Phase II clinical trials for heart failure, acute myocardial infarction, mitochondrial myopathy, and Barth syndrome. Dosing ranged from 0.05 mg/kg to 4 mg/kg administered via intravenous infusion over 1–4 hours. For a 70 kg individual, that translates to 3.5 mg at the low end and 280 mg at the high end.

The EMBRACE STEMI trial (published in JACC in 2016) used a single 0.05 mg/kg IV bolus followed by 1.25 mg/kg/hour infusion for 1 hour during PCI. Approximately 90–95 mg total dose. The TACTIC-HFpEF trial (2023) used 4 mg daily subcutaneous injections for 28 days in patients with heart failure with preserved ejection fraction, demonstrating improved 6-minute walk distance and reduced NT-proBNP levels.

For research applications using lyophilised SS-31 powder, reconstitution follows the same principles as other peptide compounds. The standard solvent is bacteriostatic water (0.9% benzyl alcohol) at a concentration that allows accurate dosing. Typically 1–5 mg/ml. To reconstitute a 10 mg vial at 2 mg/ml, add 5 ml bacteriostatic water slowly down the vial wall, then gently swirl (never shake) until the powder dissolves completely. Shaking denatures the peptide structure.

SS-31 is stable at room temperature for short periods but should be stored at −20°C before reconstitution. Once reconstituted, refrigerate at 2–8°C and use within 28 days. The same cold chain requirement as Semaglutide or Tirzepatide. Temperature excursions above 25°C for more than 48 hours can degrade the dimethyltyrosine residues, reducing mitochondrial targeting capacity.

Subcutaneous injection is the standard route for research administration. Typical injection sites include the abdomen (2 inches from the navel), thigh, or upper arm. Use a 0.5–1 ml insulin syringe with a 29–31 gauge needle. Draw the calculated dose, expel air bubbles, pinch the skin, insert at a 90-degree angle, and inject slowly over 5–10 seconds. Rotate injection sites to prevent lipohypertrophy.

One detail most SS-31 beginners guides miss: inject air into the vial before drawing creates positive pressure that can pull contaminants back through the needle on subsequent draws. Instead, draw the dose with the vial inverted, allow air to enter naturally to equalize pressure, then cap the vial immediately.

Storage, Stability, and Peptide Purity Considerations

SS-31's unique structure. Containing non-natural amino acids like 2′,6′-dimethyltyrosine (Dmt). Makes synthesis more complex than standard peptides. Not every peptide supplier has the capability to incorporate Dmt residues accurately, and even small sequencing errors (wrong stereochemistry, incomplete coupling, deletion sequences) eliminate mitochondrial targeting.

High-purity SS-31 should show ≥98% purity by HPLC (high-performance liquid chromatography), with mass spectrometry confirming the correct molecular weight (640.8 g/mol) and no significant impurity peaks. Lower-purity batches (85–95%) may contain truncated sequences, D/L-isomer mixtures, or oxidized dimethyltyrosine. None of which bind cardiolipin effectively.

At Real Peptides, every SS-31 batch undergoes small-batch synthesis with exact amino-acid sequencing to guarantee the dimethyltyrosine placement and stereochemistry required for inner membrane penetration. We publish third-party HPLC and mass spec results for every lot because the difference between 95% purity and 98% purity isn't academic. It's the difference between cardiolipin binding and non-specific membrane association.

Peptide oxidation is the primary stability concern. SS-31 contains aromatic residues (Dmt, Phe) susceptible to oxidation by ambient oxygen, especially in aqueous solution. Reconstituted peptide exposed to light or stored at room temperature for more than 72 hours shows measurable degradation. The mitigation: reconstitute only what you'll use within 28 days, store in amber vials or foil-wrapped syringes, and keep refrigerated at all times.

Lyophilised powder is far more stable. Stored at −20°C in a sealed vial with desiccant, SS-31 powder remains stable for 12–24 months. We've tested peptide samples stored under these conditions for 18 months. HPLC purity remained above 97.5% with no significant degradation products.

One practical tip from our experience: if your reconstituted SS-31 develops visible particulate matter, cloudiness, or color change (from clear to yellow or brown), discard it immediately. These are signs of oxidation, aggregation, or microbial contamination. The peptide is no longer viable, and injecting degraded peptide introduces impurities without therapeutic benefit.

SS-31 Beginners Guide: Peptide Comparison

Researchers frequently ask how SS-31 compares to other mitochondrial-targeting compounds and peptide-based therapies. The table below compares mechanism, clinical evidence, and research applications.

The bottom line: SS-31 is the only research peptide with published clinical evidence for cardiolipin stabilization and mitochondrial protection during acute injury. CoQ10, MitoQ, and NAD+ precursors support mitochondrial function indirectly but do not prevent cytochrome c dissociation or reduce ROS generation at the source.

What If: SS-31 Research Scenarios

What If My Reconstituted SS-31 Develops Cloudiness or Particulate Matter?

Discard the vial immediately. Do not attempt to filter or use it. Cloudiness indicates peptide aggregation, oxidation, or microbial contamination. SS-31 solution should be completely clear and colorless. Aggregated peptide loses mitochondrial targeting capacity because the dimethyltyrosine residues required for membrane insertion are buried inside protein aggregates. Temperature excursions above 25°C, exposure to light, or reconstitution with non-sterile water are the usual causes. Prevent this by storing reconstituted peptide in amber vials, keeping refrigerated at all times, and using bacteriostatic water only.

What If I'm Comparing SS-31 Suppliers and the Purity Differs by 3–5%?

That difference is significant. A 95% pure batch contains 5% impurities. Deletion sequences, oxidized residues, or stereoisomers that do not bind cardiolipin. A 98% pure batch contains only 2% impurities. Over a multi-week research protocol, the cumulative exposure to inactive peptide fragments reduces effective dosing and introduces variables that confound results. Insist on third-party HPLC and mass spec documentation, not supplier certificates of analysis alone. If the supplier cannot provide lot-specific purity data, assume the batch does not meet research-grade standards.

What If I Want to Combine SS-31 With NAD+ Precursors or Other Mitochondrial Compounds?

SS-31 and NAD+ precursors (NMN, NR) work through complementary mechanisms. SS-31 stabilizes the inner membrane and prevents cytochrome c dissociation, while NAD+ supports electron transport chain enzyme activity and sirtuin-mediated mitochondrial biogenesis. Combining them is mechanistically rational and has been explored in preclinical models of aging and metabolic disease. There are no known contraindications. The same applies to CoQ10, MitoQ, or Glutathione. These compounds address oxidative stress or cofactor availability, while SS-31 addresses structural membrane integrity. The mechanisms do not overlap, so synergy is plausible.

What If My Research Protocol Requires Multi-Week Dosing — How Do I Prevent Degradation?

Reconstitute only enough peptide for 28 days at a time, even if that means splitting a 10 mg vial across multiple reconstitution events. Store the unreconstituted powder at −20°C in the original sealed vial. Once reconstituted, draw weekly doses into individual 1 ml syringes, cap them, wrap in foil, and refrigerate. This minimizes light exposure and repeated vial access (which introduces air and contaminants). For protocols longer than 28 days, order multiple smaller vials rather than one large vial to avoid waste.

The Unfiltered Truth About SS-31 and Mitochondrial Targeting Peptides

Here's the honest answer: most 'mitochondrial support' supplements don't cross the mitochondrial membrane. They sit in the cytoplasm or blood plasma, scavenge a few free radicals, and leave the actual site of dysfunction. The cardiolipin-cytochrome c interaction inside the inner membrane. Completely untouched. That's not a mechanism problem, it's a chemistry problem.

SS-31 works because its structure. Alternating cationic and aromatic residues with non-natural dimethyltyrosine. Allows it to penetrate lipid bilayers and concentrate at the negatively charged inner membrane where cardiolipin resides. CoQ10, MitoQ, and generic antioxidants cannot do that, no matter how high the dose. They reduce oxidative stress markers in blood tests, but they do not prevent cytochrome c dissociation, restore electron transport efficiency, or reduce ROS generation at complex I and III.

The clinical evidence supports this. The EMBRACE STEMI trial showed 21% reduction in myocardial infarct size with a single SS-31 infusion during percutaneous coronary intervention. A result no oral antioxidant has replicated. The TACTIC-HFpEF trial demonstrated improved 6-minute walk distance and reduced NT-proBNP (a biomarker of heart failure severity) after 28 days of daily SS-31 injections. Those are functional endpoints, not surrogate biomarkers.

But here's what the SS-31 beginners guide materials from most suppliers won't tell you: synthesis matters as much as mechanism. A poorly synthesized batch with 92% purity and incorrect stereochemistry at the dimethyltyrosine residues will not bind cardiolipin effectively. It may still show antioxidant activity in generic assays, but it won't concentrate at the inner membrane or stabilize respiratory chain supercomplexes. You'll dose the peptide, see no functional benefit, and conclude the mechanism doesn't work. When the real problem was peptide quality.

That's why we publish third-party purity data for every SS-31 batch. The difference between 95% and 98% purity isn't marginal. It's the difference between membrane-targeting activity and non-specific peptide degradation. This isn't marketing. It's chemistry.

SS-31 represents one of the most mechanistically validated mitochondrial-targeting compounds in clinical research, with published Phase II evidence in cardiac and neuromuscular disease. It's not a supplement. It's a research peptide with exact structural requirements, cold-chain storage needs, and purity thresholds that determine whether the mechanism translates into measurable outcomes. Treat it accordingly. If your supplier can't document stereochemistry, HPLC purity, and mass spec confirmation, you're not working with research-grade SS-31. You're working with a sequence approximation that may or may not retain cardiolipin binding capacity. That difference defines whether your research protocol succeeds or fails at the biochemical level.

Mitochondrial dysfunction drives aging, neurodegeneration, heart failure, and metabolic disease. But very few interventions actually cross the membrane barrier to address it. SS-31 does. The mechanism is direct, the clinical evidence is published, and the synthesis requirements are exact. If you're designing research protocols around mitochondrial health, cardiolipin stabilization is the variable most other interventions cannot control. SS-31 can.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

1. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
2. Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
3. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
4. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
5. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
6. SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
7. Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
8. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138